Gilde Healthcare portfolio company Nyxoah realizes successful IPO at Nasdaq - Gilde Healthcare

Gilde Healthcare portfolio company Nyxoah realizes successful IPO at Nasdaq

July 2, 2021
Utrecht (the Netherlands) & Mont-Saint-Guibert (Belgium)

Gilde Healthcare portfolio company Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today started trading on NASDAQ. Gross proceeds of the initial public offering (IPO) before deducting underwriting costs amount to US$ 85.1 million. In addition, Nyxoah has granted the underwriters a 30-day option to purchase up to an additional 425,250 ordinary shares at the IPO price less underwriting costs, if any. The closing of the Offering is expected to occur on July 7, 2021.

Nyxoah’s ordinary shares are listed on Euronext Brussels and today began trading on the NASDAQ Global Market under the same symbol “NYXH”.

Piper Sandler, Stifel and Cantor are acting as joint book-running managers for the offering. Degroof Petercam is acting as a co-manager.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio® system, a CE-marked, patient-centered, minimally invasive, next generation hypoglossal neurostimulation therapy for treatment of moderate to severe OSA. OSA is the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for potential CE-mark indication expansion, the DREAM IDE pivotal study for potential FDA approval and the post-marketing EliSA study in Europe to evaluate the long-term safety and efficacy of the Genio® system. For more information, please visit www.nyxoah.com.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion across two fund strategies: Venture & Growth and Private Equity. The Venture & Growth fund of Gilde Healthcare invests in medtech, healthtech and therapeutics in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.

Media Contacts:
Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022